Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Article

ESI Most Cited Paper Industry Collaboration International Collaboration

cited authors

  • Choueiri, Toni K.; Eto, Masatoshi; Motzer, Robert; De Giorgi, Ugo; Buchler, Tomas; Basappa, Naveen S.; Mendez-Vidal, Maria Jose; Tjulandin, Sergei; Park, Se Hoon; Melichar, Bohuslav; Hutson, Thomas; Alemany, Carlos; McGregor, Bradley; Powles, Thomas; Gruenwald, Viktor; Alekseev, Boris; Rha, Sun Young; Kopyltsov, Evgeny; Kapoor, Anil; Gordoa, Teresa Alonso; Goh, Jeffrey C.; Staehler, Michael; Merchan, Jaime R.; Xie, Ran; Perini, Rodolfo F.; Mody, Kalgi; McKenzie, Jodi; Porta, Camillo

authors

Publication Date

  • March 1, 2023

webpage

published in

category

start page

  • 228

end page

  • 238

volume

  • 24

issue

  • 3